Penn Medicine to Conduct New Clinical Trial to Evaluate Safety and Efficacy of Chewing Gum Designed by School of Dental Medicine Researchers to Trap SARS-CoV-2 in Saliva
The trial will recruit participants from a pool of Penn Medicine employees whose responses to the PennOpen Pass screening system indicate that they may be infected with COVID-19.
OptiDX: An AI-Powered Optical Tool for Fluorescence-Guided Oncological Surgery
Feredun Azari, M.D., Sardar Azari, and Sunil Singhal, M.D., co-invented OptiDx, an AI-powered optical tool for fluorescence-guided oncological surgery.
Penn Spinout Interius BioTherapeutics Is Developing Tools to Perform Cell and Gene Engineering Directly in the Human Body
The hope is that this new technology could simplify the process of CAR-T cell therapy and make gene therapy widely available as a one-time injection to a much larger number of patients.
NCI Grant for New Cancer Telehealth Research Center of Excellence
The University of Pennsylvania (Penn) Telehealth Research Center in Cancer Care (Penn TRACE) will become one of four NCI Telehealth Research Centers of Excellence.
Announcing The Penn Institute for RNA Innovation
The Penn Institute for RNA Innovation is a new institute dedicated to the understanding and development of all aspects of RNA from basic to translational science.
Katie Reuther on The Future of Penn Health-Tech and Penn’s Thriving Innovation Ecosystem
Penn Health-Tech is well known for turning innovative ideas across the health system into useful technologies and products that solve problems and advance health care.
Penn Gene-Editing Spinout iEcure Receives Rare Pediatric Disease Designation from FDA for Lead Drug Candidate
iEcure is developing the new drug candidate, GTP-506, as a treatment for a rare genetic condition caused by a genetic defect in a liver enzyme responsible for detoxification of ammonia.
Carl June Discusses Applications of CAR-T Cell Therapy in Science Friday Interview
In this Science Friday interview, Dr. Carl June discusses CAR-T's continued use in battling new blood cancers, as well as its future potential for treating solid state cancers and autoimmune diseases.
Penn-invented CAR-T Therapy Achieves Unprecedented Milestone
"We have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me."
Penn Spinout REGENXBIO Inc. Enters Commercial Phase; Focuses Gene Therapy on Common Cause of Blindness
Regenxbio's gene therapy would eliminate the need for wet AMD patients to visit their doctor every few months to receive a needle in their eye to treat their condition.